Zydus Lifesciences Acquires Two US-Based Biologics Facilities in $141M Deal with Agenus

Zydus Lifesciences Ltd. has entered into a definitive agreement with Agenus Inc., acquiring two biologics manufacturing facilities in Emeryville, CA, and Berkeley, CA for an upfront consideration of $75 million. The deal also includes contingent payments of up to $50 million over the next three years, linked to production orders for botensilimab and balstilimab (BOT/BAL).

 

Key Highlights of the Agreement:

Outlook on Zydus’ Expansion in Biologics

This acquisition marks a major milestone in Zydus’ global expansion strategy, strengthening its biologics manufacturing capabilities and positioning it as a key player in immuno-oncology therapeutics. The partnership with Agenus is expected to accelerate clinical development and enhance patient access to advanced cancer treatments.

 

Sources: Yahoo Finance, TMCnet.